E. Williams

Pulmonary and Systemic Pharmacokinetics of Inhaled and Intravenous Colistin Methanesulfonate in Cystic Fibrosis Patients: Targeting Advantage of Inhalational Administration

Shalini Wickramaratne Senarath Yapa, Jian Li, Kashyap Patel et al. · Antimicrobial Agents and Chemotherapy · 2014 · 159 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis

Giulia Spoletini, L. Gillgrass, K. Pollard et al. · Journal of Cystic Fibrosis · 2022 · 95 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Improvement in exercise duration, lung function and well-being in G551D-cystic fibrosis patients: a double-blind, placebo-controlled, randomized, cross-over study with ivacaftor treatment

Deirdre Edgeworth, D. Keating, Matthew J. Ellis et al. · Clinical Science · 2017 · 61 citations

Medicine, Physiology, Exercise Physiology +16

Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension

Susannah J. King, Audrey Tierney, Deirdre Edgeworth et al. · Nutrition · 2021 · 47 citations

Medicine, Pharmacology, Pharmacotherapy +15

Algorithm to control "effect compartment" drug concentrations in pharmacokinetic model-driven drug delivery

James Jacobs, E. Williams · IEEE Transactions on Biomedical Engineering · 1993 · 46 citations

Pharmacy, Pharmacokinetics, Pharmacology +14